Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Executive Summary

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Advertisement

Related Content

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei
New Company, Big Goal: Serial Entrepreneur Jonathan Lim Launches Erasca To 'Erase Cancer'
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Sage Gets More Time For Zulresso Launch Preparations With Delay Of US FDA Approval
Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin
IPO Is Next Finance Target For Hookipa Biotech After $60m Series C
Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders
Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel